Cargando…
The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
BACKGROUND: Service gaps exist in oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) in primary care. The purpose of this study was to explore the clinical effectiveness of a community dwelling Atrial Fibrillation Special Clinic (AFSC) run by primary care physicians by evaluat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926793/ https://www.ncbi.nlm.nih.gov/pubmed/36788489 http://dx.doi.org/10.1186/s12875-023-02004-w |
_version_ | 1784888351864651776 |
---|---|
author | Lau, Ka Man Leung, To Fung Li, Yim Chu Chen, Catherine Xiao Rui |
author_facet | Lau, Ka Man Leung, To Fung Li, Yim Chu Chen, Catherine Xiao Rui |
author_sort | Lau, Ka Man |
collection | PubMed |
description | BACKGROUND: Service gaps exist in oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) in primary care. The purpose of this study was to explore the clinical effectiveness of a community dwelling Atrial Fibrillation Special Clinic (AFSC) run by primary care physicians by evaluating its impact on OAC use and the control of modifiable cardiovascular disease (CVD) risk factors in high risk AF patients. METHOD: Quasi-experimental study was conducted in AFSC run by public primary care physicians in Hong Kong. Study subjects were high risk AF patients with CHA(2)DS(2)-VASc scores ≥ 2, who had been followed up (FU) at AFSC for at least one year from 01 August, 2019 to 31 October, 2020. OAC usage and modifiable CVD risk factor control were compared before and after one year of FU at AFSC. Drug-related adverse events, emergency attendance or hospitalisation episodes, survival and mortality rates after one year FU at AFSC were also reviewed. RESULTS: Among the 299 high risk AF patients included in the study, significant increase in OAC use was observed from 58.5% at baseline to 82.6% after one year FU in AFSC (P < 0.001). Concerning CVD risk factor control, the average diastolic blood pressure level was significantly reduced (P = 0.009) and the satisfactory blood pressure control rate in non-diabetic patients was markedly improved after one year FU (P = 0.049). However, the average HbA1c and LDL-c levels remained static. The annual incidence rate of ischaemic stroke/systemic embolism was 0.4%, intra-cranial haemorrhage was 0.4%, major bleeding episode was 3.2% and all-cause mortality was 4.3%, all of which were comparable to reports in the literature. CONCLUSION: AFSC is effective in enhancing OAC use and maintaining optimal modifiable CVD risk factor control among high risk AF patients managed in primary care setting, and therefore may reduce AF-associated morbidity and mortality in the long run. |
format | Online Article Text |
id | pubmed-9926793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99267932023-02-15 The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community Lau, Ka Man Leung, To Fung Li, Yim Chu Chen, Catherine Xiao Rui BMC Prim Care Research BACKGROUND: Service gaps exist in oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) in primary care. The purpose of this study was to explore the clinical effectiveness of a community dwelling Atrial Fibrillation Special Clinic (AFSC) run by primary care physicians by evaluating its impact on OAC use and the control of modifiable cardiovascular disease (CVD) risk factors in high risk AF patients. METHOD: Quasi-experimental study was conducted in AFSC run by public primary care physicians in Hong Kong. Study subjects were high risk AF patients with CHA(2)DS(2)-VASc scores ≥ 2, who had been followed up (FU) at AFSC for at least one year from 01 August, 2019 to 31 October, 2020. OAC usage and modifiable CVD risk factor control were compared before and after one year of FU at AFSC. Drug-related adverse events, emergency attendance or hospitalisation episodes, survival and mortality rates after one year FU at AFSC were also reviewed. RESULTS: Among the 299 high risk AF patients included in the study, significant increase in OAC use was observed from 58.5% at baseline to 82.6% after one year FU in AFSC (P < 0.001). Concerning CVD risk factor control, the average diastolic blood pressure level was significantly reduced (P = 0.009) and the satisfactory blood pressure control rate in non-diabetic patients was markedly improved after one year FU (P = 0.049). However, the average HbA1c and LDL-c levels remained static. The annual incidence rate of ischaemic stroke/systemic embolism was 0.4%, intra-cranial haemorrhage was 0.4%, major bleeding episode was 3.2% and all-cause mortality was 4.3%, all of which were comparable to reports in the literature. CONCLUSION: AFSC is effective in enhancing OAC use and maintaining optimal modifiable CVD risk factor control among high risk AF patients managed in primary care setting, and therefore may reduce AF-associated morbidity and mortality in the long run. BioMed Central 2023-02-14 /pmc/articles/PMC9926793/ /pubmed/36788489 http://dx.doi.org/10.1186/s12875-023-02004-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lau, Ka Man Leung, To Fung Li, Yim Chu Chen, Catherine Xiao Rui The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
title | The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
title_full | The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
title_fullStr | The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
title_full_unstemmed | The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
title_short | The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
title_sort | effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926793/ https://www.ncbi.nlm.nih.gov/pubmed/36788489 http://dx.doi.org/10.1186/s12875-023-02004-w |
work_keys_str_mv | AT laukaman theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT leungtofung theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT liyimchu theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT chencatherinexiaorui theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT laukaman effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT leungtofung effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT liyimchu effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity AT chencatherinexiaorui effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity |